Shares of Biolase (BIOL +16%) pops after posting upbeat Q4 guidance, now expecting revenues above $18M, primarily due to the increased demand for its flagship WaterLase iPlus and its new EPIC 10 soft tissue diode laser. The company also noted that it's expecting a substantial acceleration in the adoption of lasers over the next few years. Analysts are looking for $17.9M in revenues, putting the company's projection in-line to just slightly ahead of estimates.
Shares of Biolase (BIOL +16%) pops after posting upbeat Q4 guidance, now expecting revenues...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs